Navigation Links
Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Date:8/11/2008

CALGARY, Aug. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN(R) in combination with docetaxel (Taxotere(R)) in patients with advanced cancers including bladder, prostate, lung and upper gastro-intestinal. The principal investigator is Professor Hardev Pandha of the Royal Surrey Hospital, U.K.

The trial (REO 010) has two components. The first is an open-label, dose-escalating, non-randomized study of REOLYSIN(R) given intravenously with docetaxel every three weeks. Standard dosages of docetaxel were delivered to patients with escalating dosages of REOLYSIN(R) intravenously. The second component of the trial includes the enrolment of a further nine patients at the top dose of REOLYSIN(R) in combination with a standard dosage of docetaxel.

"We have completed the dose escalation stage of the study," said Prof. Pandha. "Patients enrolled had previously undergone significant treatment with combination chemotherapy. The combination of REOLYSIN(R) and taxotere was safe, well tolerated with no obvious toxicity related specifically to REOLYSIN(R). Efficacy of the combination was encouraging: both objective anti-tumour responses and disease stabilization were observed radiologically."

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including bladder, lung, prostate or upper gastro-intestinal cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN(R) when administered in combination with docetaxel. Secondary objectives include the evaluation of immune resp
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... NEW YORK , July 29, 2015 /PRNewswire/ ... neuropathology testing, announces increased partnerships with VA and ... offers Epidermal Nerve Fiber Density (ENFD) and Sweat ... of small fiber neuropathy ( https://therapath.com/skin ). ... Epidermal Nerve Fiber Density (ENFD) on punch skin ...
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation ... combination products , in particular, drug/device combinations. The current system received a score of ... Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Finding gooey or ... is quite normal. Although there are a considerable number of terms in popular use ... this post-sleep material is a mixture of mucus, blood cells, skin cells and dust, ...
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... Costello ... new levee system to protect the Orange County, Texas area from future storm ... multi-firm design team in determining several potential levee alignment alternatives for providing protection, Costello ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Preventing Storm Surge Flooding in Houston 2
... from North Carolina State University have found a way to ... for technologies ranging from drug delivery to molecular sensors. The ... length for DNA strands used in self-assembly not too ... contain genetic coding that will form bonds with another strand ...
... Md., Oct. 28 PharmAthene, Inc. (NYSE Amex: ... and chemical threats, today announced that it intends to offer ... public offering. The offering is subject to market conditions and ... the offering may be completed, or as to the actual ...
... 28 Midwest health care startups reported $572 million ... three quarters of 2010, according to the BioEnterprise ... Similar to last year, while ... years, the number of companies financed remains the same. ...
Cached Biology Technology:Researchers find 'Goldilocks' of DNA self-assembly 2PharmAthene Announces Proposed Common Stock Offering 2PharmAthene Announces Proposed Common Stock Offering 3Midwest Health Care Startups Raise $572 Million Through Q3 2010 2Midwest Health Care Startups Raise $572 Million Through Q3 2010 3
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, ... expected revenues in 2015 that relate to sales of FPC1025 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... in China and we are proud that ... for Axon , its first ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... In this week's Analytical Chemistry, scientists at Indiana ... sperm cells to follow the weakest of scents. ... some sperm cells still found their mark. , ... response to a chemical gradient) can be downloaded ...
... predict which smokers using the nicotine patch are likely to ... probability of success in quitting cigarettes, according to the results ... of Clinical Pharmacology and Therapeutics. , The blood ... nicotine is metabolized, may eventually be performed non-invasively using saliva ...
... Unlike the Three Musketeers who lived by the motto ... to do their own thing. For years, debate swirled ... on a central growth regulatory module. Now, the cooperation ... for Biological Studies. They show that each hormone acts ...
Cached Biology News:Even when faint, ovary scent draws sperm cells 2Blood test predicts success of quitting smoking using the nicotine patch 2Computational analysis shows that plant hormones often go it alone 2Computational analysis shows that plant hormones often go it alone 3
2,4-Dinitrophenyl hapten is conjugated to Keyhole Limpet (KLH) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
ANTI GELSOLIN...
Biology Products: